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Dendritic cells (DC), the primary antigen presenting
cells and stimulators of naïve immune cells, are uniquely
positioned to promote anti-tumor immunity. We devel-
oped a DC vaccine which expresses three full length
melanoma antigens tyrosinase, MART-1, and MAGE-A6
engineered with an Ad type 5 adenovirus “AdVTMM2”
which can activate CD8+ and CD4+ T cells as well as
natural killer (NK) cells. A clinical trial testing this vac-
cine as well as the potential effects of IFN-a administra-
tion post-vaccination has enrolled 36 patients to date
(NCT01366144). Peripheral blood banked at baseline,
post-DC vaccination, and after either observation or one
month of high dose IFN-a was tested for anti-tumor
immunity. Here, we present initial immune response
testing of the 12 HLA-A2+ patients who were able to be
assessed for circulating CD8+ T cell frequencies by
HLA-A2-peptide dextramers. Patient PBMCs were ana-
lyzed by MHC dextramer binding assay to determine 1) the
frequency of CD8+ cells specific to vaccine encoded anti-
gens in the subset of HLA-A2+ patients and 2) potential
determinant spreading to antigens not in the vaccine,
3) frequency and co-expression of the checkpoint inhibitor
molecules CTLA-4, PD-1, and TIM-3 on CD8+ T cells, and
4) to characterize three NK cell subpopulations. On the
CD8+ T cells, PD-1 was the checkpoint molecule most
commonly expressed, while CTLA-4 was minimally
expressed. TIM-3 was the checkpoint molecule most com-
monly expressed on all three subpopulations of NK cells.
We observed that most patients developed vaccine-encoded
antigen-specific responses, and a subset demonstrated
determinant spreading to non-vaccine encoded antigens
gp100 and/or NY-ESO-1. Expression of checkpoint
molecules changed on both T and NK cells through the
treatment periods, and the function (by IFNg ELISPOT)
was also assessed. This study will aid in the design of more
effective dendritic cell vaccines and adjuvants for metastatic
melanoma patients.
Trial registration
ClinicalTrials.gov identifier NCT01366144.
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